Iron Triangle Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Iron Triangle Partners’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,820,915	Closed	-$27.2M	–	29
2025 Q3	$27.2M	Buy	1,820,915 +325,032	+22%	+$3.96M	3.87%	12
2025 Q2	$17.4M	Sell	1,495,883 -638,178	-30%	-$5.8M	2.68%	17
2025 Q1	$15.9M	Buy	+2,134,061	New	+$16.4M	2.5%	22
2020 Q3	–	Sell	-150,000	Closed	-$7.26M	–	26
2020 Q2	$7.26M	Hold	150,000	–	–	1.83%	23
2020 Q1	$4.17M	Hold	150,000	–	–	1.61%	25
2019 Q4	$4.49M	Buy	+150,000	New	+$4.31M	1.19%	23

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Iron Triangle Partners's ADPT Position: Q4 2025 in Review

Iron Triangle Partners sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 1,820,915 shares — an estimated $27.2M sold.

Iron Triangle Partners first reported a position in ADPT in Q4 2019 and held it in 6 quarters. The position peaked at $27.2M in Q3 2025. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

Iron Triangle Partners reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
Iron Triangle Partners sold 1,820,915 Adaptive Biotechnologies shares in Q4 2025, an estimated $27.2M.
Iron Triangle Partners first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 6 quarters.
Iron Triangle Partners's Adaptive Biotechnologies position peaked at $27.2M in Q3 2025.
283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.